Hemophilia A and B are rare X‐linked inherited bleeding disorders caused by complete or
partial deficiency in or the absence of coagulation factors VIII and IX. Recurrent joint …

Background and Purpose The methodological quality of randomized controlled trials (RCTs)
is commonly evaluated in order to assess the risk of biased estimates of treatment effects …

Background Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy
vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX …

Background Effective ways to prevent arthropathy in severe hemophilia are unknown.
Methods We randomly assigned young boys with severe hemophilia A to regular infusions …

Background: Prevention of arthropathy is a major goal of hemophilia treatment. While
studies in adults have demonstrated an impact of prophylaxis on the incidence of joint …

Background: Prophylaxis with factor (F) VIII is considered the optimal treatment for managing
hemophilia A patients without inhibitors. Objectives: To compare the efficacy of two …

Prophylactic treatment in severe hemophilia is very effective but is limited by cost issues.
The implementation of 2 different prophylactic regimens in The Netherlands and Sweden …

Proteins Biochemistry and Biotechnology 2e is a definitive source of information for all those
interested in protein science, and particularly the commercial production and isolation of …

Prophylactic clotting-factor regimens reduce the occurrence of bleeding episodes and
maintain joint health in individuals with moderate and severe hemophilia. However, these …

Hemophilia A is an X-linked hereditary bleeding disorder due to the deficiency of
coagulation factor VIII (FVIII). According to the degree of FVIII deficiency, mild, moderate or …